甲状腺毒症中长效甲状腺刺激物保护剂水平与甲状腺 131-I 摄取率的相关性
Correlation between long-acting thyroid stimulator protector level and thyroid 131-I uptake in thyrotoxicosis.
作者信息
Adams D D, Kennedy T H, Stewart R D
出版信息
Br Med J. 1974 Apr 27;2(5912):199-201. doi: 10.1136/bmj.2.5912.199.
Abstract
Out of 50 consecutive untreated patients with diffuse toxic goitre 15 showed long-acting thyroid stimulator (LATS), 30 showed LATS protector only, and five showed neither. LATS protector was present in all the patients with LATS. Infiltrative ophthalmopathy was less common in patients with LATS protector only (40%) than in patients with LATS also (67%), but the difference was not significant. There was a correlation between LATS protector level and thyroid (131)I uptake rate factor (k(1)), the coefficient (r) being 0.68 (P < 0.001). LATS level showed no such correlation. The results support the hypothesis that LATS protector is a pathogenic thyroid stimulator in patients with diffuse toxic goitre.
摘要
在50例未经治疗的连续性弥漫性毒性甲状腺肿患者中，15例显示有长效甲状腺刺激素（LATS），30例仅显示有LATS保护物，5例两者均未显示。所有有LATS的患者均有LATS保护物。仅具有LATS保护物的患者（40%）发生浸润性眼病的情况比同时有LATS的患者（67%）少见，但差异无显著性。LATS保护物水平与甲状腺（131）I摄取率因子（k(1)）之间存在相关性，系数（r）为0.68（P < 0.001）。LATS水平未显示出此类相关性。这些结果支持了LATS保护物是弥漫性毒性甲状腺肿患者中一种致病性甲状腺刺激物的假说。
相似文献
1
Correlation between long-acting thyroid stimulator protector level and thyroid 131-I uptake in thyrotoxicosis.甲状腺毒症中长效甲状腺刺激物保护剂水平与甲状腺 131-I 摄取率的相关性
Br Med J. 1974 Apr 27;2(5912):199-201. doi: 10.1136/bmj.2.5912.199.
2
LATS protector and abnormal thyroid stimulation in diffuse toxic goitre.弥漫性毒性甲状腺肿中的LATS保护因子与异常甲状腺刺激
N Z Med J. 1975 Jan 8;81(531):24.
3
Effects of long-acting thyroid stimulator (LATS) and LATS protector on human thyroid adenyl cyclase activity.长效甲状腺刺激素（LATS）和LATS保护物对人甲状腺腺苷酸环化酶活性的影响。
Br Med J. 1973 Jul 14;3(5871):72-5. doi: 10.1136/bmj.3.5871.72.
4
Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.未经治疗的甲状腺毒症中的长效甲状腺刺激素（LATS）和长效甲状腺刺激素保护物（LATS-P）。
Clin Endocrinol (Oxf). 1981 Jun;14(6):631-9. doi: 10.1111/j.1365-2265.1981.tb02975.x.
5
Dissociation of serum LATS activity and hyperfunction and autonomy of the thyroid gland in Graves' disease.格雷夫斯病中血清长效甲状腺刺激素活性与甲状腺功能亢进及自主性的分离。
J Clin Endocrinol Metab. 1975 Jun;40(6):935-41. doi: 10.1210/jcem-40-6-935.
6
Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.一名患有桥本甲状腺炎、长效甲状腺刺激素（LATS）和LATS保护因子均为阴性但甲状腺刺激抗体阳性的女性所分娩的婴儿出现短暂性甲状腺毒症。
J Clin Endocrinol Metab. 1982 Feb;54(2):354-6. doi: 10.1210/jcem-54-2-354.
7
Evidence that mouse thyroid stimulator does not stimulate the human thyroid gland.小鼠甲状腺刺激素不会刺激人类甲状腺的证据。
Aust N Z J Med. 1976 Aug;6(4):300-4. doi: 10.1111/imj.1976.6.4.300.
8
LATS-protector activity in thyrotoxicosis measured by thyroidal intracellular colloid droplet formation.通过甲状腺细胞内胶体滴形成来测量甲状腺毒症中LATS保护因子的活性。
J Clin Endocrinol Metab. 1978 May;46(5):841-8. doi: 10.1210/jcem-46-5-841.
9
Evidence that both long-acting thyroid stimulator and long-acting thyroid stimulator-protector stimulate the human thyroid gland.长效甲状腺刺激素和长效甲状腺刺激素保护剂均可刺激人体甲状腺的证据。
J Endocrinol. 1979 Feb;80(2):215-21. doi: 10.1677/joe.0.0800215.
10
Evidence to suggest that LATS protector stimulates the human thyroid gland.有证据表明LATS保护剂会刺激人体甲状腺。
J Clin Endocrinol Metab. 1971 Jul;33(1):47-51. doi: 10.1210/jcem-33-1-47.
引用本文的文献
1
Autoimmunity in endocrine disease.内分泌疾病中的自身免疫
Proc R Soc Med. 1974 Jun;67(6 Pt 2):548-56. doi: 10.1177/00359157740676P207.
2
Concentration-dependent regulation of thyrotropin receptor function by thyroid-stimulating antibody.促甲状腺素受体功能受甲状腺刺激抗体的浓度依赖性调节。
J Clin Invest. 2004 Jun;113(11):1589-95. doi: 10.1172/JCI21334.
3
Clinical significance of classification of Graves' disease according to the characteristics of TSH receptor antibodies.根据促甲状腺激素受体抗体特征对格雷夫斯病进行分类的临床意义
Korean J Intern Med. 2001 Sep;16(3):187-200. doi: 10.3904/kjim.2001.16.3.187.
4
The thyrotrophin receptor.促甲状腺激素受体
Springer Semin Immunopathol. 1982;5(4):413-31. doi: 10.1007/BF01857428.
5
Thyroid stimulating immunoglobulins. The Watson Smith lecture 1983.促甲状腺素受体抗体。1983年沃森·史密斯讲座
J R Coll Physicians Lond. 1984 Jul;18(3):155-60.
6
Autoimmune mice make anti-Fc gamma receptor antibodies.自身免疫小鼠会产生抗Fcγ受体抗体。
J Exp Med. 1990 May 1;171(5):1581-95. doi: 10.1084/jem.171.5.1581.
7
Editorial: hyperthyroidism and Grave's disease.社论：甲状腺功能亢进症与格雷夫斯病
Br Med J. 1975 May 31;2(5969):457-8. doi: 10.1136/bmj.2.5969.457.
8
Peripheral blood leucocytes in thyrotoxicosis (Graves' disease) as studied by conventional light microscopy.用传统光学显微镜研究甲状腺毒症（格雷夫斯病）患者的外周血白细胞。
Clin Exp Immunol. 1977 Feb;27(2):216-21.
9
Determination of thyroid stimulating immunoglobulins (TSI) during the course of Graves' disease. A reliable indicator for remission and persistence of this disease?格雷夫斯病病程中促甲状腺素受体抗体（TSI）的测定。这是该疾病缓解和持续存在的可靠指标吗？
J Endocrinol Invest. 1978 Apr;1(2):155-61. doi: 10.1007/BF03350364.
本文引用的文献
1
ASSESSMENT OF THYROID FUNCTION BY THE COMBINED USE OF THE SERUM PROTEIN-BOUND IODINE AND RESIN UPTAKE OF 131-I-TRIIODOTHYRONINE.联合使用血清蛋白结合碘和131-I-三碘甲状腺原氨酸树脂摄取量评估甲状腺功能
J Clin Endocrinol Metab. 1965 Jan;25:39-45. doi: 10.1210/jcem-25-1-39.
2
ISOLATION AND IDENTIFICATION OF THE LONG-ACTING THYROID STIMULATOR AND ITS RELATION TO HYPERTHYROIDISM AND CIRCUMSCRIBED PRETIBIAL MYXEDEMA.长效甲状腺刺激素的分离、鉴定及其与甲状腺功能亢进和局限性胫前黏液性水肿的关系
J Clin Endocrinol Metab. 1964 Oct;24:1005-28. doi: 10.1210/jcem-24-10-1005.
3
Fractionation of plasma containing the long acting thyroid stimulator.对含有长效甲状腺刺激素的血浆进行分级分离。
J Biol Chem. 1962 Nov;237:3571-2.
4
The presence of an abnormal thyroid-stimulating hormone in the serum of some thyrotoxic patients.一些甲状腺毒症患者血清中存在异常促甲状腺激素。
J Clin Endocrinol Metab. 1958 Jul;18(7):699-712. doi: 10.1210/jcem-18-7-699.
5
Thyroid function assay with radioiodine. II. Routine calculation of thyroidal and renal rate factors.放射性碘甲状腺功能测定。II. 甲状腺和肾脏速率因子的常规计算。
J Clin Invest. 1955 Jan;34(1):106-14. doi: 10.1172/JCI103052.
6
Classification of the eye changes of Grave's disease.格雷夫斯病眼部病变的分类。
J Clin Endocrinol Metab. 1969 Jul;29(7):982-4. doi: 10.1210/jcem-29-7-982.
7
Comparison of the thyroid-stimulating hormone content of serum from thyrotoxic and euthyroid people.甲状腺功能亢进者与甲状腺功能正常者血清中促甲状腺激素含量的比较。
J Clin Endocrinol Metab. 1969 Jul;29(7):900-3. doi: 10.1210/jcem-29-7-900.
8
Evidence to suggest that LATS protector stimulates the human thyroid gland.有证据表明LATS保护剂会刺激人体甲状腺。
J Clin Endocrinol Metab. 1971 Jul;33(1):47-51. doi: 10.1210/jcem-33-1-47.
9
Direct evidence for human thyroidal stimulation by LATS-protector.长效甲状腺刺激素保护物对人体甲状腺刺激的直接证据。
J Clin Endocrinol Metab. 1973 Mar;36(3):517-21. doi: 10.1210/jcem-36-3-517.
10
The pathogenesis of Graves' disease. A disorder of delayed hypersensitivity?格雷夫斯病的发病机制。一种迟发型超敏反应紊乱？
Mayo Clin Proc. 1972 Nov;47(11):824-34.
Zotero 插件